Home Cart Sign in  
Chemical Structure| 935693-62-2 Chemical Structure| 935693-62-2

Structure of BIX-01294
CAS No.: 935693-62-2

Chemical Structure| 935693-62-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BIX-01294 is a reversible and highly selective G9a and GLP histone methyltransferase inhibitor with IC50 values of 1.7 μM and 0.9 μM, respectively. BIX-01294 competes for binding with amino acids N-terminal of the substrate lysine residue, inducing necroptosis and autophagy, and has antitumor activity in recurrent tumor cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BIX-01294

CAS No. :935693-62-2
Formula : C28H38N6O2
M.W : 490.64
SMILES Code : CN1CCN(C2=NC(NC3CCN(CC4=CC=CC=C4)CC3)=C5C=C(OC)C(OC)=CC5=N2)CCC1
MDL No. :MFCD14560563
InChI Key :OSXFATOLZGZLSK-UHFFFAOYSA-N
Pubchem ID :25150857

Safety of BIX-01294

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of BIX-01294

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bladder cancer cell line J82 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
Bone cancer cell line U2OS 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
Brain cancer cell line U251 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
Breast cancer cell lines MCF10A and MCF7 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
Cervical cancer cell line HeLa 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
Colon cancer cell lines HCT116 and RKO 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
Liver cancer cell line Hep2G 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
Lung cancer cell line H1299 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
Sympathetic nervous system cancer cell lines BE(2)-C, SMS-KCNR, and SHEP1 2–5 µM 1-6 days Significantly reduced the global levels of H3K9me1 and H3K9me2 and completely inhibited the proliferation of all the cancer cell lines examined Cell Metab. 2013 Dec 3;18(6):896-907.
DPSCs 1 µM 2 weeks BIX-01294 significantly promotes the chondrogenic differentiation of DPSCs, as indicated by the augmented expression levels of cartilage-signature markers and markedly increased proteoglycans. Adv Sci (Weinh). 2023 Aug;10(24):e2206757.
HCT116 cells 5 µM 24 hours To examine the effect of BIX-01294 on FOXO1 methylation, results showed decreased FOXO1 methylation levels Nucleic Acids Res. 2019 Feb 28;47(4):1692-1705.
DLD-1 cells 5 µM 24 hours To examine the effect of BIX-01294 on FOXO1 methylation, results showed decreased FOXO1 methylation levels Nucleic Acids Res. 2019 Feb 28;47(4):1692-1705.
SW480 cells 5 µM 24 hours To examine the effect of BIX-01294 on FOXO1 methylation, results showed decreased FOXO1 methylation levels Nucleic Acids Res. 2019 Feb 28;47(4):1692-1705.
HEY cells 5 µM 24 hours BIX-01294 significantly up-regulated the transcriptional expression of SLC31A1 and reduced the IC50 value of CDDP, increasing CDDP sensitivity. EBioMedicine. 2021 Sep;71:103558.
SKOV3 cells 5 µM 24 hours BIX-01294 significantly up-regulated the transcriptional expression of SLC31A1 and reduced the IC50 value of CDDP, increasing CDDP sensitivity. EBioMedicine. 2021 Sep;71:103558.
JEG-3 placental choriocarcinoma cells 3.3 µM 3 days BIX-01294 showed an IC50 value of 3.3 µM in JEG-3 cells, demonstrating selectivity for the parasite. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16708-13.
Human foreskin fibroblasts (HFF) 6.1 µM 3 days BIX-01294 showed an IC50 value of 6.1 µM in HFF cells, demonstrating selectivity for the parasite. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16708-13.
Mouse embryonic fibroblasts (MEF) 11 µM 3 days BIX-01294 showed an IC50 value of 11 µM in MEF cells, demonstrating selectivity for the parasite. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16708-13.
Plasmodium falciparum 3D7 100 nM 3 hours BIX-01294 and TM2-115 inhibited P. falciparum 3D7 parasites in culture with IC50 values of ∼100 nM, and significantly reduced parasite viability within 3 hours. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16708-13.
KG1 cells 10 µM 48 hours BIX-01294 activated the PERK/NRF2 pathway and upregulated HO-1 expression, suppressing p38 phosphorylation and intracellular ROS generation, thereby inhibiting apoptosis in KG1 cells. J Exp Clin Cancer Res. 2020 Apr 15;39(1):66.
U937 cells 10 µM 48 hours BIX-01294 markedly induced p38 phosphorylation and apoptosis in U937 cells. J Exp Clin Cancer Res. 2020 Apr 15;39(1):66.
EGFR-mutant NSCLC cells (PC9 and H1975) 10 µM 48 hours BIX significantly induced apoptosis and activated effector caspase-3 and PARP. Exp Mol Med. 2021 Dec;53(12):1877-1887.
EGFR-WT NSCLC cells (H460 and A549) 10 µM 48 hours BIX had no significant apoptotic effect on EGFR-WT cells. Exp Mol Med. 2021 Dec;53(12):1877-1887.
K-ras NIH 3T3 transformed cells 2.5 µM 72 hours BIX-01294 treatment reversed Ras-mediated epigenetic silencing of the Fas gene, similar to the effect of 5-aza treatment. Nat Struct Mol Biol. 2009 Mar;16(3):312-7.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Plasmodium berghei ANKA infection model Intraperitoneal injection 40 mg/kg Single dose A single intraperitoneal dose of 40 mg/kg BIX-01294 reduced parasitemia by 2-fold in mice, and the mice survived for more than 3 weeks post-infection. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16708-13.
Nude mice Intra-peritoneal tumor model Intra-peritoneal injection 5 mg/kg Twice a week for six weeks BIX-01294 significantly reduced tumor growth and prolonged the survival time of tumor-bearing mice, increasing CDDP sensitivity. EBioMedicine. 2021 Sep;71:103558.
Severe combined immunodeficiency mice EGFR-mutant NSCLC xenograft model Intraperitoneally 5 mg/kg or 10 mg/kg 2 days a week for 4 weeks BIX significantly inhibited the growth of EGFR-mutant tumors and reduced EGFR expression. Exp Mol Med. 2021 Dec;53(12):1877-1887.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.04mL

0.41mL

0.20mL

10.19mL

2.04mL

1.02mL

20.38mL

4.08mL

2.04mL

References

 

Historical Records

Categories